| Subject: | FDA Requires Warnings about Risk of Suicidal Thoughts and Behavior for Antiepileptic Medications |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 17 Dec 2008 - 12:00 pm |
| The U.S. Food and Drug Administration (FDA) is requiring the manufacturers of anti-epileptic drugs to add to the prescribing information or labeling, a warning that the use of anti-epileptic drugs increases risk of suicidal thoughts and behaviors. The action includes all antiepileptic drugs including those used to treat psychiatric disorders, migraine headaches and other conditions, as well as epilepsy. For each of these products, the FDA is also requiring the manufacturers submit a Risk... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
